Question to the Ministry of Defence:

To ask the Secretary of State for Defence, with reference to the Ministry of Defence accounts 2024-25, what did the Melorius write-off and constructive losses of £12,552,000 relate to.

Initiated to replace an in-service capability, MELORIUS was a Chemical, Biological, Radiological and Nuclear (CBRN) Medical Countermeasure project to rapidly develop and provide immediate treatment to a person exposed to a Nerve Agent.

A Commercial Off The Shelf (COTS) product became available during the development stage of the project, following changes in the commercial market. Project MELORIUS was re-evaluated and a decision was made to stop further development, with funds reinvested into procuring a COTS solution. This represented the best value for money for the taxpayer, a low-risk option and significantly reduced the delivery timescales.

The constructive loss of £12,552,000 was incurred during the active management of stopping project MELORIUS. It relates to the safe disposal of 110,000 medical devices, a necessary up-front purchase, and the associated costs of development and testing of the products.

In delivering the best capabilities for our Armed Forces, it is vital that we continually review the market and emerging technologies for ways to enhance our current offering, to ensure that our troops have what they need to operate effectively and the ability to respond to evolving threats.